scholarly journals Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

2007 ◽  
Vol 39 (3) ◽  
pp. 359-365 ◽  
Author(s):  
Wayne A Cabral ◽  
Weizhong Chang ◽  
Aileen M Barnes ◽  
MaryAnn Weis ◽  
Melissa A Scott ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

scholarly journals Erratum: Corrigendum: Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta

2008 ◽  
Vol 40 (7) ◽  
pp. 927-927 ◽  
Author(s):  
Wayne A Cabral ◽  
Weizhong Chang ◽  
Aileen M Barnes ◽  
MaryAnn Weis ◽  
Melissa A Scott ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

Camurati-Engelmann disease (progressive hereditary craniodiaphyseal dysplasia)

1978 ◽  
Vol 48 (1) ◽  
pp. 138-142 ◽  
Author(s):  
John K. Yen ◽  
Robert S. Bourke ◽  
A. John Popp ◽  
Carl R. Wirth
Keyword(s):  
Optic Nerve ◽  
Definitive Treatment ◽  
Content Type ◽  
X Ray ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder ◽  
Craniodiaphyseal Dysplasia ◽  
Engelmann Disease ◽  
Fine Print

✓ In a patient with Camurati-Engelmann disease, orbital and optic nerve decompression resulted in improvement of papilledema. Subsequent x-ray films of the optic canals, however, revealed reconstitution of osseous optic canals bilaterally, and papilledema has returned in one eye. Definitive treatment of this dysplastic metabolic bone disorder rests in the control of rapid abnormal bone formation.

scholarly journals Gnathic Bones and Hyperparathyroidism: A Review on the Metabolic Bony Changes Affecting the Mandible and Maxilla in case of Hyperparathyroidism

2020 ◽  
Vol 2020 ◽  
pp. 1-6
Author(s):  
Hazim Mahmoud Ibrahem
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Giant Cell ◽  
Essential Role ◽  
Osteolytic Lesion ◽  
Ossifying Fibroma ◽  
Brown Tumor ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

Parathyroid glands secrete the parathyroid hormone that plays an essential role in bone remodeling. Excessive production of parathyroid hormone causes a common metabolic bone disorder known as hyperparathyroidism that is classified into primary, secondary, or tertiary. In hyperparathyroidism, the late bony complication is manifested as a giant cell osteolytic lesion called “brown tumor.” Primary hyperparathyroidism is usually a sporadic disorder, but in minority of cases it occurs in inherited forms, and one of these forms is the hyperparathyroidism-jaw tumor syndrome, which is characterized by primary hyperparathyroidism and ossifying fibroma in the mandible and/or maxilla.

scholarly journals Bone markers in metabolic bone disorder in patients on chronic hemodialysis and kidney transplant recipients

2006 ◽  
pp. 137-149
Author(s):  
Danijela Zupanic ◽  
Jelena Vlasic-Tanaskovic ◽  
Ruzica Smalcelj ◽  
Petra Kes ◽  
Vesna Kusec
Keyword(s):  
Kidney Transplant ◽  
Bone Markers ◽  
Chronic Hemodialysis ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

scholarly journals Diabetes Mellitus and Metabolic Bone Disorder.

1999 ◽  
Vol 57 (3) ◽  
pp. 125-134 ◽  
Author(s):  
Kiyoshi Suzuki ◽  
Makoto Takizawa ◽  
Eiji Itagaki ◽  
Hitoshi Ishida
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Bone Disorder

Comparing the efficacies of bisphosphonates’ therapies for osteoporosis persistence and compliance: A Systematic Review

2021 ◽  
Vol 21 ◽  
Author(s):  
Faisal I. Almohaileb ◽  
Zafar Rasheed
Keyword(s):  
Systematic Review ◽  
Literature Search ◽  
Persistence Length ◽  
Medication Possession Ratio ◽  
Cochrane Library ◽  
Treatment Of Osteoporosis ◽  
Metabolic Bone Disorder ◽  
Metabolic Bone ◽  
Persistence Rates ◽  
Bone Disorder

Objectives: Osteoporosis is the most prevalent metabolic bone disorder worldwide. This review was undertaken to compare the efficacies of bisphosphonates therapies for patient persistence and compliance for the treatment of osteoporosis. Methods: A systematic review was performed in accordance with the available reporting items. MEDLINE and Cochrane library databases were applied for literature searched up to January 2020. All major studies such as prospective, retrospective and reviews articles that examined patient persistence or compliance to bisphosphonates for osteoporosis were included. Results: Literature search found 656 relevant published reports, out of which 87 were included. The 10,712,176 osteoporotic patients were studied for patient persistence and 5,875,718 patients were studied for patient compliances. Analysis of all studied bisphosphonates showed almost similar patterns for patient persistence rates as it was decreased over the time following initial prescription but persistence length was found to be significantly high for alendronate therapy as compared to the other studied bisphosphonates (p<0.001), whereas the length of persistence of all other bisphosphonates (other than alendronate) were almost same (p>0.05). Analysis of patient compliances with etidronate therapy showed the highest percent medication possession ratio (MRP) at 12 months, followed by the MRPs of ibandronate, alendronate, risedronate, and clodronate. Conclusions: This is the first systematic review that shows the comparison of the efficiencies of bisphosphonates for patient persistence and compliance for the treatment of osteoporosis. The data showed that the length of patient persistence was highest for alendronate therapy, whereas patient compliance was highest for etidronate therapy for the treatment of osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document